Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
14 hedge funds and large institutions have $28.8M invested in Verona Pharma in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.
1.02% more ownership
Funds ownership: 5.55% → 6.58% (+1%)
0% more funds holding
Funds holding: 14 → 14 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
15% less capital invested
Capital invested by funds: $33.7M → $28.8M (-$4.89M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$8.19M |
| 2 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$476K |
| 3 |
CCFM
Clear Creek Financial Management
Silverdale,
Washington
|
+$206K |
| 4 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
+$7.13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
-$2.3M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$120K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$88K |
| 4 |
Renaissance Technologies
New York
|
-$72K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$55.7K |
VRNA Hedge Fund Activity: Q1 2020 in Review
14 of the 4,540 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q1 2020, worth a combined $28.8M — down 15% from $33.7M a quarter earlier.
Fund positioning in VRNA was balanced in Q1 2020: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 4 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $8.19M. The largest seller was venBio Partners, cutting an estimated $2.3M.
- 14 institutional investors held Verona Pharma (VRNA) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $28.8M of Verona Pharma stock for Q1 2020, down 15% quarter-over-quarter.
- 3 funds opened new Verona Pharma positions in Q1 2020 and 3 closed out, a net change of 0 holders.
- The largest Verona Pharma buyer in Q1 2020 was Vivo Capital, an estimated $8.19M added.
- The largest Verona Pharma seller in Q1 2020 was venBio Partners, an estimated $2.3M sold.
Based on aggregated 13F filings for Q1 2020.